NCT02659306View on ClinicalTrials.gov

Metformin Immunotherapy in HIV Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

August 14, 2018

Study Completion Date

February 29, 2020

Conditions
HIV Infection
Interventions
DRUG

Metformin

Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.

Trial Locations (1)

H4A 3J1

Chronic Viral Illness Service, McGill University Health Centre, Montreal

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02659306 - Metformin Immunotherapy in HIV Infection | Biotech Hunter | Biotech Hunter